Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | KLK7 | P49862 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17922893 | 1.00 | HSD17B10 (0.42) | HSD17B10ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL17922929 | 1.00 | HSD17B10 (0.42) | HSD17B10ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL16031033 | 0.79 | HSD17B10 (0.42) | HSD17B10ALDH1A1SMN1; SMN2CTSKHPGD | |
| SCHEMBL16031037 | 0.79 | HSD17B10 (0.42) | HSD17B10ALDH1A1SMN1; SMN2CTSKHPGD | |
| SCHEMBL16148112 | 0.79 | HSD17B10 (0.42) | HSD17B10ALDH1A1SMN1; SMN2CTSKHPGD | |
| SCHEMBL21408159 | 0.77 | HSD17B10 (0.42) | HSD17B10ALDH1A1SMN1; SMN2CTSKHPGD | |
| SCHEMBL24845877 | 0.76 | HSD17B10 (0.39) | HSD17B10ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL27172955 | 0.76 | HSD17B10 (0.39) | HSD17B10ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL26248934 | 0.76 | SMN1; SMN2 (0.37) | HSD17B10ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL18740754 | 0.76 | NR1H2 (0.37) | HSD17B10ALDH1A1SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160221948-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-08-04 | — | — | US | disclosed |
| EP-3045448-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | Sumitomo Chemical Company Limited (JP) | 2016-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160221948-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, H1-4, HRH4 | HSD17B10 1292/4885ALDH1A1 2734/4885SMN1; SMN2 1489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.